Chugai Pharmaceutical Co. Ltd (CHGCF PINK) stock market data APIs
$48.3805
-4.44(-9.2%)
as of October 17, 2025
Try our APIs with
free plan!
Chugai Pharmaceutical Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Prev. Close
48.3805
Open
43.9408
High
48.3805
Low
43.9408
52 wk Range
31.2254-70.0029
Market Cap
80 722 M
P/E Ratio
30.8491
Shares Outstanding
1 646 M
Revenue
1 196 214 M
Dividends (Yield)
0.0137
Beta
0.665
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Chugai Pharmaceutical Co. Ltd data using free add-ons & libraries
Get Chugai Pharmaceutical Co. Ltd Fundamental Data
Chugai Pharmaceutical Co. Ltd Fundamental data includes:
- Net Revenue: 1 196 214 M
- EBITDA: 588 813 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-24
- EPS/Forecast: 73.28
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Chugai Pharmaceutical Co. Ltd News
New
Rani Therapeutics (RANI) Is Up 257.9% After $1.08 Billion Chugai Deal and $60M Fundraise—What’s Changed
Rani Therapeutics Holdings recently announced a collaboration and license agreement with Chugai Pharmaceutical for the joint development and commercialization of an oral product combining Rani’s Ran...
Top Midday Gainers
Rani Therapeutics (RANI) said on Friday that it signed a collaboration and licensing agreement value PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Rani Therapeutics Enters Into Up to $1.09 Billion Collaboration, License Deal With Chugai Pharmaceutical -- Shares Rise Premarket
Rani Therapeutics (RANI) said Friday that it has signed a collaboration and licensing deal valued at PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing
Rani Therapeutics, LLC Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milest...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
